Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis



Status:Completed
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 65
Updated:3/31/2019
Start Date:August 2007
End Date:May 2009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of Ruxolitinib When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in
patients with active, stable plaque psoriasis.


Inclusion Criteria:

- Subjects must have psoriatic lesions measuring protocol specific BSA

Exclusion Criteria:

- Lesions solely involving the palms of the hands, the soles of the feet, the
intertriginious areas, the scalp or the face

- Pustular psoriasis or erythroderma
We found this trial at
4
sites
Clinical Trial Facility in Austin Texas
Austin, Texas 78744
?
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Trial Facility in College Station Texas
College Station, Texas 77845
?
mi
from
College Station, TX
Click here to add this to my saved trials
Clinical Trial Facility in Fridley Minnesota
Fridley, Minnesota 55432
?
mi
from
Fridley, MN
Click here to add this to my saved trials
Clinical Trial Facility in Rochester New York
Rochester, New York
?
mi
from
Rochester, NY
Click here to add this to my saved trials